# Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

Study · id `cardio:ct-nct03207945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03207945](<https://clinicaltrials.gov/study/NCT03207945>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03207945

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

## Technical summary

Registry record NCT03207945. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-30 (actual); primary completion 2025-08-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 118 participants (enrolled count; ClinicalTrials.gov record NCT03207945, source copy `cardio:ctgov-nct03207945-2026-08-24`, retrieved 2026-10-31)
- Started: 2018-04-30 (actual) (ClinicalTrials.gov record NCT03207945, source copy `cardio:ctgov-nct03207945-2026-08-24`, retrieved 2026-10-31)
- Primary completion: 2025-08-24 (actual) (ClinicalTrials.gov record NCT03207945, source copy `cardio:ctgov-nct03207945-2026-08-24`, retrieved 2026-10-31)
- Completion: 2025-09-24 (actual) (ClinicalTrials.gov record NCT03207945, source copy `cardio:ctgov-nct03207945-2026-08-24`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03207945, source copy `cardio:ctgov-nct03207945-2026-08-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03207945-2026-08-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
- Acronym: EPIC-HIV
- Condition: Dyslipidemias
- Condition: Cardiovascular Diseases
- Condition: HIV Infections
- Intervention (Drug): Alirocumab
- Intervention (Other): Placebo
- Lead sponsor: University of California, San Francisco
- Lead sponsor class: OTHER
- Collaborator: Massachusetts General Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: University of California, San Francisco (`cardio:org-university-of-california-san-francisco`)
- Registry lists this organization as a collaborator: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)

## Provenance

Content hash: eba239ad34dcffe310eca4fe125c8fcdd1dce6887c334def79ac74a41710eff6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
